Recent findings from a Phase 2b/3 study have revealed that blarcamesine, an investigational agent developed by Anavex Life Sciences, demonstrates significant efficacy in treating early Alzheimer’s disease. The study, which included 508 participants, showcased notable reductions in pathological amyloid-ß levels in plasma and slowed brain atrophy, offering a glimmer of hope for patients and their […]